The study aims to assess the safety and immunogenicity of mRNA-based influenza vaccine candidates.
Phase 1/2 dose-ranging study
Evaluated vaccine candidates in healthy adults
Assessed safety and immunogenicity outcomes
Vaccine candidates were well-tolerated
Demonstrated sufficient immunogenicity
Further development warranted for pandemic preparedness
Abstract
Vaccine candidates were sufficiently well-tolerated and immunogenic. Further development of mRNA pandemic influenza vaccines is warranted for pandemic preparedness.